Wuhan Hiteck Biological Pharma announced that the company has participated in the tenth batch of national Pharmaceutical centralized procurement. According to the proposed selection results released by the Central Procurement Office, the company's injection of rosuvastatin hydrochloride acetate and the injection of theobromine are proposed to be selected for this centralized procurement. These two Pharmaceutical products are suitable for the treatment of upper gastrointestinal bleeding and peripheral artery disease, respectively. The procurement cycle will be from the execution date of the selection results until December 31, 2027, during which Medical Institutions will give priority to using the selected Pharmaceutical products. The company obtained the "Pharmaceutical Registration Certificate" for the above Pharmaceutical products in 2024, but has not generated sales revenue this year. This selection will help enhance the company's brand influence and have a positive impact on the company's development.